Malaria Endgame: India’s Scientific Push Against a Silent Parasite

Why in the News?

1. India plans to eliminate malaria by 2030, but the disease still survives in tribal and remote areas. These areas are now the toughest to cover.
2. In July 2025, India launched AdFalciVax, its first home-grown malaria vaccine that targets both infection and transmission.
3. Scientists in India and around the world are testing new vaccines and mosquito control methods to deal with changing malaria parasites and resistant mosquitoes.

Key Highlights

1. India’s Uneven Malaria Burden
   1. Malaria cases dropped by over 80% between 2015 and 2023, showing major progress.
   2. However, some tribal districts like Lawngtlai (Mizoram) and Narayanpur (Chhattisgarh) still have very high infection rates.
   3. These areas often lack easy access to healthcare, making them persistent hotspots.
2. Two Malaria Parasites: Falciparum and Vivax
   1. India faces Plasmodium falciparum (causes severe illness) and Plasmodium vivax (can hide in the liver and cause relapses).
   2. In states like Jharkhand, mixed infections (both falciparum and vivax together) make up about 20% of cases.
   3. Many people have no visible symptoms (asymptomatic), but still carry the parasite, making detection harder.
3. Current Vaccines and Their Limits
   1. RTS,S (approved in 2021): Gives 55% protection in the first year, but drops over time and needs 4 doses.
   2. R21/Matrix-M (approved in 2023): Shows up to 77% protection and requires fewer doses. It is made in India by the Serum Institute.
   3. Both vaccines only target one stage of the malaria parasite (before it enters the blood), so reinfection is still possible.
4. New Vaccine Approaches Being Tested
   1. Whole-parasite vaccines like PfSPZ use a weakened form of the full parasite. These mimic natural infection and showed up to 79% protection.
   2. The PfRH5 vaccine works at the blood stage (when symptoms appear) and protects against many malaria strains.
   3. Transmission-blocking vaccines (TBVs) stop the parasite inside the mosquito, preventing its spread to others.
5. India’s Vaccine Innovation: AdFalciVax
   1. AdFalciVax, launched by ICMR in 2025, is India’s first vaccine that targets both early-stage parasite and mosquito transmission.
   2. It combines multiple antigens (PfCSP for infection + Pfs230 & Pfs48/45 for transmission).
   3. In lab tests on mice, it showed over 90% protection, worked for over 4 months, and stayed stable at room temperature for 9 months.
   4. India is also working on a vivax-specific vaccine, since vivax is harder to eliminate due to relapse.

Implications

1. Targeted Solutions for Tribal and Remote Areas
   1. Vaccines like AdFalciVax can be especially useful in tribal and hard-to-reach areas, where other methods like bed nets or spraying are harder to use.
   2. Its ability to stay stable at room temperature for 9 months makes it easier to store and transport in villages without cold storage facilities.
2. India Becomes a Global Contributor in Malaria Research
   1. With AdFalciVax and other new vaccines under development, India is now developing and testing its own advanced malaria vaccines, not just importing them.
   2. This helps India become more self-reliant and a stronger player in global health innovation.
3. Better Strategies for Breaking the Transmission Chain
   1. Many people in India carry malaria parasites without showing symptoms (asymptomatic carriers).
   2. Transmission-blocking vaccines (TBVs) stop the parasite inside the mosquito, preventing it from spreading to others, even if the person shows no signs of illness.
   3. This makes TBVs especially useful in India’s situation.
4. Introduction of Cutting-Edge Science
   1. New types of vaccines are being tested:
      1. Ferritin nanoparticle (tiny protein-based shells) + CpG adjuvant (substances that boost immune response) vaccine showed 95% reduction in liver-stage malaria in mice.
      2. mRNA vaccines (like in COVID-19) are being tried to create faster, more flexible vaccines.

• One such vaccine (using Pfs25, a sexual-stage parasite protein) blocked transmission in mice for 6 months after just 2 doses.

2. Engineered antibodies, like v-IgG, are designed to block how the parasite hides from the immune system.
3. These new tools offer stronger, longer, and more accurate protection compared to older vaccines.

5. Model for Controlling Other Infectious Diseases
   1. India’s approach, using a mix of vaccines, mosquito control, immune boosters, and local health systems, creates a complete disease-fighting model.
   2. This model can be used to fight other diseases like dengue, kala-azar, and chikungunya, especially in poor or remote areas.

Challenges and Way Forward

Conclusion

India is in the final phase of the malaria fight, but this stage is the hardest. With smarter vaccines like AdFalciVax, advanced science like CRISPR and mRNA, and focus on hidden and remote cases, the country is moving closer to its 2030 goal. However, success will depend on public health coordination, regulatory support, and strong political will. This is not just a disease elimination plan, it is a test of how science, innovation, and governance can work together to defeat a centuries-old threat.